ISM indicates indolent systemic mastocytosis (SM); SSM, smoldering SM; BMM, isolated bone marrow mastocytosis; BM, bone marrow; MC, mast cell; LNP, lymphadenopathy; PG, prostaglandin; UNL, upper normal limit; Cr, creatinine; NS, not significant; n/a, not applicable; and -, unknown or not done. SSM is defined by the presence of 2 or more "B-findings" (ie, BM MC Ͼ 30% or serum tryptase Ͼ 200 ng/mL, BM hypercellularity or dysmyelopoiesis without cytopenias, and organomegaly and/or lymphadenopathy without functional impairment). Causes of death were available for 14 of the 26 deaths: disease transformation (n ϭ 4; all SSM), cardiovascular (n ϭ 3; all ISMo), solid tumor (n ϭ 4; 3 ISMo and 1 BMM), complications of MC mediator release (n ϭ 2; 1 each SSM and ISMo), and infection (n ϭ 1; SSM). *As defined in Lim et al. 2 †Either palpable or detected by imaging studies.
responses, whereas strong T-cell responses were expected to be generated against nonpermissive mismatches. 3, 4 Clinical analysis of different patient cohorts indeed showed a significant higher risk of mortality in the nonpermissive mismatched group compared with the permissive mismatched group. However, the risk of GVHD and relapse did not significantly differ between these groups, implying that the effect on overall survival may not have directly resulted from differences in alloreactivity. 3, 5, 6 To analyze whether permissive HLA-DPB1 specific immune responses occur in vivo, we analyzed immune responses in 2 patients responding to donor lymphocyte infusion (DLI) after HLA-A, -B, -C, -DRB1, -DQB1 matched, HLA-DPB1 mismatched SCT. The patients received a permissive or nonpermissive HLA-DPB1 mismatched SCT, respectively. CD4 ϩ T cells were isolated from peripheral blood obtained during the clinical immune response to DLI, and stimulated with HLA-class II negative HeLa cells transduced with the specific HLA-DP molecules derived from patient or donor. In both patients, HLA-DP specific CD4 ϩ T cells were demonstrated by CD137 up-regulation in response to stimulation with HeLa cells transduced with patient and not donor HLA-DP molecules ( Figure  1A ). CD137 expressing CD4 ϩ T cells were clonally isolated and specific recognition of patient HLA-DP molecules was confirmed for 58% to 78% of the T-cell clones ( Figure 1B ). T-cell receptor-V␤ analysis showed a polyclonal origin of these HLA-DPB1 specific CD4 ϩ T-cell responses.
To demonstrate the generation of HLA-DP specific immune responses directed against permissive and nonpermissive HLA-DPB1 mismatches in different persons, we developed a model to generate allo-HLA-DP responses in vitro. Purified CD4 ϩ T cells of 4 different responders were stimulated with HeLa cells transduced with permissive (n ϭ 2) or nonpermissive (n ϭ 2) HLA-DPB1 molecules. Fourteen days after stimulation, CD4 ϩ T cells were restimulated with HeLa cells transduced with HLA-DP molecules used for stimulation and HeLa cells transduced with responder HLA-DP molecules. Stimulation with permissive and nonpermissive mismatched HLA-DPB1 molecules both resulted in the generation of HLA-DP specific CD4 ϩ T cells as measured by specific interferon ␥ (IFN-␥) production in response to the HLA-DP molecules used for stimulation ( Figure 1C) .
In conclusion, we demonstrated that in vivo both permissive and nonpermissive HLA-DPB1 mismatches resulted in strong polyclonal immune responses. Furthermore, we demonstrated in vitro for 4 additional persons that permissive and nonpermissive HLA-DPB1 responses were equally effectively generated. These data show immunogenicity of permissive mismatched HLA-DPB1 alleles. We suggest that the difference in overall survival between patients transplanted with permissive and nonpermissive HLA-DPB1 mismatched donors observed in clinical studies 3,4,6 may not result directly from differences in alloreactivity. 
